162666-31-1
162666-31-1 structure
- Name: RC-3095 acetate
- Chemical Name: RC-3095 acetate
- CAS Number: 162666-31-1
- Molecular Formula: C58H83N15O11
- Molecular Weight: 1166.37
- Catalog: Signaling Pathways GPCR/G Protein Bombesin Receptor
- Create Date: 2020-04-07 17:55:34
- Modify Date: 2025-08-30 10:14:36
-
RC-3095 acetate is a bombesin/gastrin releasing peptide receptor (GRPR) antagonist[1]. RC-3095 acetate exerts protective effects by reducing gastric oxidative injury in the arthritic mice[2].
| Name | RC-3095 acetate |
|---|
| Description | RC-3095 acetate is a bombesin/gastrin releasing peptide receptor (GRPR) antagonist[1]. RC-3095 acetate exerts protective effects by reducing gastric oxidative injury in the arthritic mice[2]. |
|---|---|
| Related Catalog | |
| Target |
Bombesin receptor; GRPR[1] |
| In Vivo | RC-3095 impairs aversive but not recognition memory in Wistar male rats[1]. RC-3095 (0.3 mg/kg or 1 mg/kg; S.C.) shows anti-inflammatory effects in 2 experimental models of arthritis, collagen-induced arthritis (CIA) and antigen-induced arthritis (AIA)[2]. Arthritic mice treated with RC-3095 show a significant reduction in the concentrations of IL-17, IL-1 , and TNF, and showed a diminished expression of GRPR[2]. Animal Model: Male Balb/c wild-type mice (weighing 18-25 gm) with AIA model; Male DBA/1J inbred mice (weighing 18-25 gm) with CIA model[2] Dosage: 1 mg/kg for AIA studies; 0.3 mg/kg or 1 mg/kg for CIA studies Administration: Injected SC twice a day for a total of 2 or 10 days for AIA studies; Administered SC twice a day for 10 days after the onset of the disease for CIA studies Result: Reduced neutrophil migration, mechanical hy pernociception, and proteoglycan loss in mice with AIA; Led to a significant reduction in arthritis clinical scores and the severity of disease in the CIA model. |
| References |
| Molecular Formula | C58H83N15O11 |
|---|---|
| Molecular Weight | 1166.37 |